Transforming growth factor β-mediated site-specific Smad linker region phosphorylation in vascular endothelial cells

• Main Authors: Kamato, Danielle, Rostam, Muhamad Ashraf, Piva, Terence J., Rezaei, Hossein B., Getachew, Robel, Thach, Lyna, Bernard, Rebekah, Zheng, Wenhua, Little, Peter J., Osman, Narin
• Format: Article
• Language: English
• Published: Wiley 2014
• Subjects: QP Physiology; RM Therapeutics. Pharmacology
• Online Access: http://irep.iium.edu.my/55283/1/5.%20Kamato-2014-Transforming%20growth%20factor%20%CE%B2-media.pdf; http://irep.iium.edu.my/55283/; http://onlinelibrary.wiley.com/doi/10.1111/jphp.12298/abstract
• Institution: Universiti Islam Antarabangsa Malaysia

Objectives Transforming growth factor (TGF)-β regulates the function of vascular endothelial cells and may be involved in endothelial dysfunction. The canonical TGF-β pathway involves TGF-β receptor-mediated carboxy-terminal phosphorylation of Smad2; however, TGF-β signalling also activates numerous serine/threonine kinases that phosphorylate Smad2 in its linker region. The expression of phosphorylated Smad linker proteins were determined following TGF-β stimulation in the absence and presence of different serine/threonine kinase inhibitors in vascular endothelial cells. Methods Proteins were quantified by Western blotting using specific antibodies to individual phosphorylated Smad2 linker region residues. Key findings TGF-β mediated the phosphorylation of all four Smad2 linker region residues of interest. Erk and Jnk specifically phosphorylate Ser245 while all mitogen-activated protein kinases phosphorylate Ser250 and Ser255. Thr220 and Ser245 are phosphorylated by phosphoinositide 3 kinase (PI3K), while Ser255 was phosphorylated by the PI3K/Akt pathway. CDK and GSK-3 were shown to phosphorylate Thr220 and Ser245. TGF-β also mediated plasminogen activator inhibitor-1 gene expression that was attenuated by p38 and CDK inhibitors. Conclusions TGF-β-mediated phosphorylation of individual serine/threonine sites in the linker region of Smad2 occurs in a highly specific manner by kinases. These phosphorylations provide an opportunity to further understand a therapeutically targeted and very specific signalling pathway in vascular endothelial cells.